Glaucoma in Seniors

Glaucoma is a group of eye diseases that damage the optic nerve — the cable connecting the eye to the brain — typically through elevated intraocular pressure (IOP), though normal-tension glaucoma occurs even with normal IOP. The optic nerve damage is irreversible: unlike a detached retina that can sometimes be re-attached, optic nerve tissue that dies cannot be regenerated. It earns the 'sneak thief of sight' nickname because the most common form — primary open-angle glaucoma — causes absolutely no pain, no redness, no visual symptoms, and no detectable changes in central vision until the disease has already destroyed 20–40% of peripheral visual field. By the time a patient notices 'something wrong' with their vision, they have already experienced significant irreversible damage. This is why glaucoma screening at regular eye exams — including IOP measurement, optic disc examination, OCT imaging of the nerve fiber layer, and visual field testing — is the only way to catch it before devastating loss occurs. Current glaucoma treatment cannot restore lost vision; it can only halt or slow further loss, making early detection essential.

The major risk factors for primary open-angle glaucoma include: (1) Age over 60 — the single largest risk factor; glaucoma prevalence doubles every decade after 40 and affects approximately 1 in 10 Americans over 80. (2) African American descent — POAG is 6–8× more prevalent in Black Americans and occurs at younger ages and higher severity; Black Americans have 3–4× higher rates of glaucoma-related blindness compared to white Americans. (3) Family history — a first-degree relative with glaucoma increases risk 3–9×. (4) Elevated IOP (ocular hypertension) — IOP above 21 mmHg raises risk substantially, though 30–40% of glaucoma occurs with normal IOP. (5) Thin central corneal thickness — a thinner cornea is associated with higher glaucoma risk independent of IOP. (6) High myopia (nearsightedness) — particularly for open-angle glaucoma. (7) Hispanic/Latino descent — second-highest prevalence group after Black Americans. (8) Diabetes and cardiovascular disease — associated with vascular optic nerve susceptibility. The American Academy of Ophthalmology recommends comprehensive eye exams every 1–2 years for adults over 40 in any high-risk category, and every 2 years starting at 40 for all adults.

Inconsistent use of glaucoma eye drops is one of the most common reasons for glaucoma progression, and adherence to glaucoma medications is a well-documented challenge — studies show 25–60% of glaucoma patients are non-adherent to their drops. The fundamental problem is that glaucoma is asymptomatic — patients feel no benefit from taking the drops and no immediate consequence from skipping them. Yet the consequence is optic nerve damage that accumulates silently until it becomes visually apparent, at which point the damage is irreversible. Even one missed dose measurably increases IOP. Strategies to improve adherence: (1) Use a combination drop that consolidates multiple medications into one bottle (Combigan = brimonidine + timolol; Cosopt = dorzolamide + timolol; Simbrinza = brinzolamide + brimonidine) — reduces drop burden from 4+ drops to 2 or 1. (2) Attach drop administration to a daily habit (bedtime for prostaglandins; morning and bedtime for twice-daily). (3) Minimize side effects by switching to a preservative-free formulation if ocular irritation is causing avoidance. (4) Sustained-release options: Durysta (biodegradable bimatoprost implant inserted into the anterior chamber) provides IOP-lowering for ~3 years without daily eye drops — a major adherence solution for senior patients.

Selective laser trabeculoplasty (SLT) is an in-office laser procedure that treats the trabecular meshwork of the eye to improve aqueous humor outflow — reducing IOP without requiring daily eye drops. It takes about 5 minutes, requires only topical anesthetic drops, and causes no incision or sutures. The LiGHT trial (Lancet, 2019) — a major UK randomized controlled trial — found that SLT as first-line treatment for newly diagnosed POAG was non-inferior to eye drops for IOP control, had a lower medication burden, and was more cost-effective. After successful SLT, approximately 70–80% of patients are drop-free for 3–5 years; the procedure can be repeated when IOP rises. SLT is particularly advantageous for: seniors who struggle with daily eye drop adherence; those with medication side effects; patients who have difficulty applying drops due to arthritis or tremor; patients already on many other medications (simplifying the regimen). SLT is not appropriate for narrow-angle glaucoma or some forms of secondary glaucoma. If your parent has been recently diagnosed with POAG or ocular hypertension, it is worth asking the ophthalmologist whether SLT is a viable first-line option before committing to lifetime eye drops.

Glaucoma's attack on peripheral vision has direct driving safety implications. Peripheral vision is critical for: detecting pedestrians and cyclists on the sides of the road, monitoring adjacent lanes and rear traffic without full head turns, detecting signals and hazards in the far visual periphery, and making safe left turns at intersections. Visual field testing for driving typically requires 120–140° of horizontal peripheral vision — glaucoma that significantly constricts the visual field can result in failing the driving vision test even when central (straight-ahead) acuity remains good. This distinction confuses many families: 'Dad reads the newspaper fine' — but glaucoma is destroying the peripheral vision that driving requires, not central reading vision. Legal thresholds vary by state, but most require specific peripheral field extents beyond just central acuity. Formal driving evaluation by a certified driver rehabilitation specialist (CDRS) is more informative than a standard DMV vision test, as it can assess actual functional driving ability with the patient's specific visual field pattern. Seniors with glaucoma should inform their ophthalmologist if they still drive — and the ophthalmologist can help determine when driving is no longer safe.

Acute angle-closure glaucoma is one of the few true ophthalmic emergencies — IOP can spike to 40–80 mmHg (normal: 10–21 mmHg) when the iris physically blocks the drainage angle suddenly. Without emergency treatment, this can cause permanent vision loss within hours. Symptoms of an acute angle-closure attack are dramatic and should not be missed: sudden severe eye pain (often described as excruciating); headache (sometimes so severe it causes nausea and vomiting, mimicking migraine or GI illness); a red eye; halos around lights (the extremely high IOP makes the cornea edematous/hazy); and vision blurring or a steamy appearance. These symptoms require emergency room evaluation — NOT a next-day ophthalmology appointment. Emergency treatment typically includes IOP-lowering eye drops, oral or IV medications to rapidly lower pressure, and definitive treatment with laser peripheral iridotomy (LPI) — a tiny laser hole in the iris that creates an alternative drainage pathway. Anatomically narrow angles (visible on gonioscopy before any attack) can be prophylactically treated with LPI before an acute attack occurs. Certain medications can precipitate angle closure in susceptible eyes — including antihistamines, tricyclic antidepressants, anticholinergics, and topiramate — which is relevant for seniors on multiple medications.

Glaucoma is a chronic disease that currently has no cure — treatment must typically continue for life. The goal of all glaucoma therapy is to slow or halt optic nerve damage by lowering IOP to a level where progression stops; this is called the 'target pressure.' However, the nature of the treatment varies: (1) Eye drops — lifelong daily administration unless replaced by SLT or surgery. (2) Selective laser trabeculoplasty (SLT) — effects last 3–5 years and can be repeated; may eliminate or reduce drops for extended periods. (3) Incisional surgery — trabeculectomy or minimally invasive glaucoma surgery (MIGS devices: iStent, Kahook Dual Blade, OMNI, XEN gel stent) can achieve IOP control that reduces or eliminates drop dependence for years; MIGS is particularly suited to mild-moderate glaucoma and is often combined with cataract surgery. (4) Endoscopic cyclophotocoagulation (ECP) — laser treatment of the ciliary body to reduce aqueous production. Despite these options, the disease requires lifelong ophthalmology follow-up to monitor IOP, nerve fiber layer thickness (OCT), and visual fields — because glaucoma can progress despite 'controlled' IOP in some patients. Progression rates and prognosis vary widely: many patients with well-controlled POAG never progress to significant visual impairment.

All three are common age-related eye conditions, but they affect different structures and cause different patterns of vision loss: Glaucoma damages the optic nerve, typically from elevated intraocular pressure — it attacks peripheral vision first, is completely asymptomatic initially, and causes irreversible damage. Treatment (drops, laser, surgery) halts progression but cannot recover lost vision. Cataracts cloud the crystalline lens of the eye — they cause gradual blurring of all vision (both central and peripheral), halos, glare, and difficulty with contrast. They are completely curable with outpatient cataract surgery, which is one of the most common surgeries in the US (4 million performed annually). Vision is restored to normal or near-normal in the vast majority of patients. Macular degeneration (AMD) damages the macula — the central retina — specifically attacking fine central vision (reading, faces, driving forward). AMD spares peripheral vision. Dry AMD progresses slowly with no treatment except AREDS2 supplements; wet AMD can cause rapid central vision loss but is now highly treatable with anti-VEGF injections. A senior can have all three conditions simultaneously — this is not rare. Each requires separate evaluation and management by the ophthalmologist.